Photo By Al Drago/CQ Roll Call

In its latest nod to digital therapeutics, the US Food and Drug Administration okayed Israeli bioelectronics company Theranica’s smartphone-controlled wearable for noninvasive treatment of migraines after showing bright results in a 250-patient study, according to mHealth Intelligence. Migraines are a pervasive illness: 39 million people in the US suffer from migraines, and it’s the third most prevalent illness globally, Migraine Research Foundation reports. And drugs to relieve migraines are often often riddled with side effects: In one study, two-thirds of migraine sufferers delayed or forewent taking their medications because of adverse effects. Digital therapeutics could offer patients a more satisfactory experience, and they could help payers put a dent in their share of costs associated with the condition: Migraine costs add up to $36 billion annually in the US.